Posts

Electra Targets Nearly $300M IPO

on
Electra Therapeutics is targeting a Nasdaq IPO of nearly $300 million in net proceeds. The biotech plans to offer about 21.7 million shares at $14–$16 each; at the $15 midpoint, gross proceeds would be roughly $325 million and net proceeds about $296.6 million. Including a possible overallotment, net proceeds could reach approximately $341.9 million. Electra expects to use the IPO funds to advance its immunology and cancer pipeline, including ipsoprubart in T/NK-cell malignancies and ELA822 in an early-stage trial. The company has applied to list under the ticker ETRA. AstraZeneca and Daiichi Sankyo reported positive Phase 3 DESTINY-Lung04 results for Enhertu in first-line treatment of advanced HER2-mutant non-small-cell lung cancer. Enhertu reduced the risk of disease progression or death by 37% versus pembrolizumab plus platinum-pemetrexed chemotherapy. Median progression-free survival was 14.3 months versus 8.3 months, while the response rate was 70.0% versus 44.5%. The tria...

GSK seeks to expand Nuvalent lung cancer drug use with new positive data

on

GSK strikes up to $750 million deal for Chimagen blood-cancer therapy

on

LBL-024 Shows Promising Early Results in First-Line NSCLC

on

Scholar Rock wins FDA approval for ISEMBYLD SMA therapy after year-long manufacturing delay

on

AstraZeneca’s Camizestrant Misses Key First-Line Breast-Cancer Trial Goal

on

Definium reports another Phase 3 win for LSD-based anxiety drug DT120

on

Scholar Rock wins FDA approval for ISEMBYLD, a muscle-targeted SMA treatment

on

Novo Nordisk seeks a reset after major setbacks

on

FDA Reassesses Rare-Disease Trial Standards and Endpoint Selection

on

GSK to wind down Dresden vaccine factory amid weak flu-vaccine demand

on

Ivonescimab Shows Survival Advantage Over Keytruda in Lung Cancer Trial

on

Cyclic peptides advance toward new drug targets, but manufacturing capacity may determine how fast

on